The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 352:2589-2597 June 23, 2005 Number 25
NextNext

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton, M.D., Robert Livingston, M.D., David Johnson, M.D., James Rigas, M.D., Michael Johnston, M.D., Charles Butts, M.D., Yvon Cormier, M.D., Glenwood Goss, M.D., Richard Inculet, M.D., Eric Vallieres, M.D., Willard Fry, M.D., Drew Bethune, M.D., Joseph Ayoub, M.D., Keyue Ding, Ph.D., Lesley Seymour, M.D., Ph.D., Barbara Graham, R.N., Ming-Sound Tsao, M.D., David Gandara, M.D., Kenneth Kesler, M.D., Todd Demmy, M.D., Frances Shepherd, M.D., for the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Pisters, K. M.W.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non–small-cell lung cancer.

Methods We randomly assigned patients with completely resected stage IB or stage II non–small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen.

Results A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. In both groups, the median age was 61 years, 65 percent were men, and 53 percent had adenocarcinomas. Chemotherapy caused neutropenia in 88 percent of patients (including grade 3 febrile neutropenia in 7 percent) and death from toxic effects in two patients (0.8 percent). Nonhematologic toxic effects of chemotherapy were fatigue (81 percent of patients), nausea (80 percent), anorexia (55 percent), vomiting (48 percent), neuropathy (48 percent), and constipation (47 percent), but severe (grade 3 or greater) toxic effects were uncommon (<10 percent). Overall survival was significantly prolonged in the chemotherapy group as compared with the observation group (94 vs. 73 months; hazard ratio for death, 0.69; P=0.04), as was relapse-free survival (not reached vs. 46.7 months; hazard ratio for recurrence, 0.60; P<0.001). Five-year survival rates were 69 percent and 54 percent, respectively (P=0.03).

Conclusions Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non–small-cell lung cancer.


Source Information

From the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont. (T.W., M.J., C.B., Y.C., G.G., R.I., D.B., J.A., K.D., L.S., B.G., M.-S.T., F.S.); Southwest Oncology Group, San Antonio, Tex. (R.L., E.V., D.G.); Eastern Cooperative Oncology Group, Boston (D.J., W.F., K.K.); and Cancer and Leukemia Group B, Chicago (J.R., T.D.).

Address reprint requests to Dr. Winton at 2D2.09 Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112th St., Edmonton, AB T6G 2B7, Canada, or at twinton{at}cha.ab.ca.

Full Text of this Article


Related Letters:

Treatment of Resected Non–Small-Cell Lung Cancer
Bria E., Giannarelli D., Terzoli E., Winton T. L., Ding K., Seymour L.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1523-1524, Oct 6, 2005. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.